Kinoshita Y
Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Shimane 693-8501, Japan.
Aliment Pharmacol Ther. 2004 Dec;20 Suppl 8:19-23. doi: 10.1111/j.1365-2036.2004.02223.x.
Management of gastro-oesophageal reflux disease (GERD) is aimed at reducing oesophageal acid exposure to achieve symptom relief. Therapy has traditionally included advice to the patient on diet and lifestyle management. Recent evidence suggests, however, that some specific dietary modifications may be applicable to the Japanese patient. For example, ingestion of Japanese sweet cakes or rice cakes should be avoided by the Japanese patient with GERD as these foods may provoke heartburn. Pharmacological therapy is, however, usually also required for effective symptom relief. While antacids and histamine H(2)-receptor antagonists have a role in treating mild GERD, effective relief of many cases of oesophagitis is usually only achieved by using proton-pump inhibitors such as lansoprazole, omeprazole and rabeprazole. In the Japanese population, variation in the genetic polymorphism of CYP2C19 (a cytochrome P450 isoenzyme) leads to considerable inter-individual unpredictability in the activity of lansoprazole and omeprazole due to inter-individual differences in the extent to which these agents are metabolized. Consequently, rabeprazole, which does not undergo hepatic biotransformation by CYP2C19, offers significant advantages over the other PPIs as a result of its more predictable activity. This, coupled with its more rapid onset of action, leads to a more efficient and less variable acid-suppressing effect.
胃食管反流病(GERD)的治疗旨在减少食管酸暴露以缓解症状。传统治疗方法包括向患者提供饮食和生活方式管理方面的建议。然而,最近的证据表明,一些特定的饮食调整可能适用于日本患者。例如,患有GERD的日本患者应避免食用日本甜蛋糕或米糕,因为这些食物可能会引发烧心。然而,通常还需要药物治疗才能有效缓解症状。虽然抗酸剂和组胺H2受体拮抗剂在治疗轻度GERD中发挥作用,但许多食管炎病例通常只有通过使用质子泵抑制剂(如兰索拉唑、奥美拉唑和雷贝拉唑)才能有效缓解。在日本人群中,CYP2C19(一种细胞色素P450同工酶)基因多态性的变异导致兰索拉唑和奥美拉唑活性在个体间存在很大的不可预测性,这是由于这些药物代谢程度的个体差异所致。因此,雷贝拉唑不经过CYP2C19的肝脏生物转化,由于其活性更可预测,与其他质子泵抑制剂相比具有显著优势。这一点,再加上其起效更快,导致抑酸效果更有效且变化更小。